Patents by Inventor Edward Fox Kleinman

Edward Fox Kleinman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6174895
    Abstract: A compound of the formula or the pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are as defined above, useful in the treatment of respiratory, allergic, rheumatoid, body weight regulation, inflammatory and central nervous system disorders such as asthma, chronic obstructive pulmonary disease, adult respiratory diseases syndrome, toxic shock, fibrosis, pulmonary hypersensitivity, allergic rhinitis, atopic dermatitis, psoriasis, weight control, rheumatoid arthritis, cachexia, Crohn's disease, ulcerative colitis, arthritic conditions and other inflammatory diseases, depression, multi-infarct dementia and AIDS.
    Type: Grant
    Filed: August 11, 1999
    Date of Patent: January 16, 2001
    Assignee: Pfizer Inc.
    Inventor: Edward Fox Kleinman
  • Patent number: 6114367
    Abstract: This invention relates to isoxazoline compounds which are inhibitors of tumor necrosis factor (TNF). The isoxazoline compounds are useful for inhibiting TNF in a mammal in need thereof and in the treatment or alleviation of inflammatory conditions or disease, including but not limited to rheumatoid arthritis, osteoarthritis, asthma, bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis, dermatitis and inflammatory bowel disease, sepsis, septic shock, tuberculosis, graft versus host disease and cachexia associated with AIDS or cancer. This invention also relates to pharmaceutical compositions useful therefor comprising such compounds.
    Type: Grant
    Filed: November 6, 1998
    Date of Patent: September 5, 2000
    Assignee: Pfizer Inc
    Inventors: Victoria Lee Cohan, Edward Fox Kleinman
  • Patent number: 5869511
    Abstract: This invention relates to isoxazoline compounds of formula (I) which are inhibitors of tumor necrosis factor (TNF). The isoxazoline compounds are useful for inhibiting TNF in a mammal in need thereof and in the treatment or alleviation of inflammatory conditions or disease, including but not limited to rheumatoid arthritis, osteoarthritis, asthma, bronchitis, chronic obstructive airways disease, psoriais, allergic rhinitis, dermatitis and inflammatory bowel disease, sepsis, septic shock, tuberculosis, graft versus host disease and cachexia associated with AIDS or cancer. This invention also relates to pharmaceutical compositions useful therefor comprising such compounds of formula (I) wherein X.sup.1 is --(CH.sub.2).sub.q OH, --CHOHR.sup.5 or --(CH.sub.2).sub.m CON(R.sup.6)(OH); wherein q and m are each independently 0 or an integer from 1 to 5; R.sup.5 is (C.sub.1 -C.sub.4)alkyl; and R.sup.6 is hydrogen or (C.sub.1 -C.sub.3)alkyl; n is 0, 1, 2 or 3; Y.sup.1 and Y.sup.2 are as defined in the application.
    Type: Grant
    Filed: September 5, 1996
    Date of Patent: February 9, 1999
    Assignee: Pfizer Inc.
    Inventors: Victoria Lee Cohan, Edward Fox Kleinman
  • Patent number: 5789408
    Abstract: Compounds of formula (I) are active antiviral compounds useful in the treatment of viral infections in mammals. The compounds of the invention are readily prepared by reaction of a suitable 2-thiothiazole derivative with an appropriate Het-(CH.sub.2).sub.n -halide.
    Type: Grant
    Filed: January 11, 1996
    Date of Patent: August 4, 1998
    Assignee: Pfizer Inc.
    Inventors: Edward Fox Kleinman, Hiroko Masamune, Vinod Dipak Parikh
  • Patent number: 5716967
    Abstract: This invention relates to isoxazoline compounds which are selective inhibitors of phosphodiesterase type IV (PDE.sub.IV). The isoxazoline compounds are useful in inhibiting PDE.sub.IV and in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease, psoriasis, allergic rhinitis, dermatitis, shock, atopic dermatitis, rheumatoid arthritis and osteoarthritis. This invention also relates to pharmaceutical compositions useful therefor.
    Type: Grant
    Filed: May 15, 1996
    Date of Patent: February 10, 1998
    Assignee: Pfizer Inc.
    Inventor: Edward Fox Kleinman
  • Patent number: 5696141
    Abstract: This invention relates to a method of inhibiting 5-lipoxygenase in a mammal in need thereof by administering compounds of the core of formula ##STR1## the racemic, racemic-diastereomeric mixtures and optical isomers of said compounds and the pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: September 5, 1996
    Date of Patent: December 9, 1997
    Assignee: Pfizer Inc.
    Inventors: Victoria Lee Cohan, Edward Fox Kleinman
  • Patent number: 5686434
    Abstract: This invention relates to 3-aryl-2-isoxazoline compounds which are selective inhibitors of phosphodiesterase type IV (PDE.sub.IV). The 3-aryl-2-isoxazolines are useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease, psoriasis, allergic rhinitis, dermatitis, shock, atopic dermatitis, rheumatoid arthritis and osteoarthritis. This invention also relates to pharmaceutical compositions useful therefor.
    Type: Grant
    Filed: May 15, 1996
    Date of Patent: November 11, 1997
    Assignee: Pfizer Inc.
    Inventor: Edward Fox Kleinman